Обзор посвящен описанию исследований, характеризующих современное состояние проблемы латентной туберкулезной
инфекции. Особое внимание уделено описанию особенностей возбудителя в латентном («дремлющем») состоянии и реакции макроорганизма на «дремлющие» микобактерии (дормантные локусы, реакции макрофагов и др.).
Ключевые слова: латентная туберкулезная инфекция, «дремлющие» микобактерии, дормантные локусы
Литвинов Виталий Ильич – научный руководитель ГБУЗ «Московский городской научно-практический центр борьбы
с туберкулезом Департамента здравоохранения города Москвы», доктор медицинских наук, профессор, академик РАН
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. +7 (499) 268-04-15
e-mail: mnpcbtlv@yandex.ru
1. Земскова З.С., Дорожкова И.Р. Скрыто протекающая туберкулезная инфекция. // М.: Медицина, 1984. – 224 с.
2. Литвинов В.И. Латентная туберкулезная инфекция – миф или реальность? // Туберкулез и болезни легких. – 2011. – № 6. – С. 3-9.
3. Литвинов В.И. Латентная туберкулезная инфекция – свойства возбудителя; реакции макроорганизма; эпидемиология и диагностика
(IGRA-тесты, ДИАСКИНТЕСТ® и другие подходы), лечение. – М.: МНПЦБТ. – 2016. – 196 с.
4. Митинская Л.А. Туберкулез у детей. – М.: ЗАО «Кудесники», 2004. – 196 с.
5. Скворцов Т.А., Ажикина Т.Л. Адаптивные изменения экспрессии генов Mycobacterium tuberculosis в ходе инфекционного процесса. //
Биоорг. химия. – 2012. – Т. 38. – С. 391-405.
6. Слогоцкая Л.В., Сенчихина О.Ю., Никитина Г.В., Богородская Е.М. Эффективность кожного теста с аллергеном туберкулезным
рекомбинантным при выявлении туберкулеза у детей и подростков Москвы в 2013 г. // Педиатрическая фармакология. – 2015. – № 1. – С. 99-103.
7. Ahmad S. Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. // Clin. Dev. Immunol. – 2011. – P. 814-943.
8. Al-Orainey I. Diagnosis of latent tuberculosis: Can we do better? // Ann. Thorac. Med. – 2009. – Vol. 4. – N. 1. – P. 5-9.
9. Andersen P., Munk M., Pollock J. et al. Specific immune-based diagnosis of tuberculosis. // Lancet. – 2000. – Vol. 356. – P. 1099-1104.
10. Barry C., Boshoff H., Dartois V. et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. // Nat. Rev. Microbiol. – 2009. –
Vol. 7. – N. 12. – P. 845-855.
11. Belay M., Legesse M., Mihret A. et al. Pro- and anti-inflammatory cytokines against Rv2031 are elevated during latent tuberculosis: a study in cohorts
of tuberculosis patients, household contacts and community controls in an endemic setting. // PLoS One. – 2015. – Vol. 10. – N. 4. – e0124134.
12. Capuano S., Croix D., Pawar S. et.al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various
manifestations of human M. tuberculosis infection // Infect. Immun. – 2003. – Vol. 71. – N. 10. – P. 5831-5844
13. Casey R., Blumenkrantz D., Millington K. et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden
in tuberculosis. // PLoS One. – 2010. – Vol. 5. – N. 12. – e15619.
14. Chao M., Rubin E. Letting sleeping dos lie: does dormancy play a role in tuberculosis?// Ann. Rev. Microbiol. – 2010. – Vol. 64. – P. 293-311.
15. Cole S., Brosch R., Parkhill J. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. // Nature. – 1998. –
Vol. 393. – P. 537-544.
16. Commandeur S., van Meijgaarden K., Prins C. et.al. An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens
targeted by human T-cells expressed during pulmonary infection // J. Immunol. – 2013. – Vol. 190. – N. 4. – P. 1659-1671.
17. Corbière V., Pottier G., Bonkain F. et al. Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. // PLoS One. –
2012. – Vol. 7. – N. 8. – e43285.
18. Demissie A., Leyten E.M., Abebe M. et al. Recognition of stage-specific mycobacterial antigens
19. Dheda K., Schwander S., Zhu B. et al. The immunology of tuberculosis: from bench to bedside. // Respirology. – 2010. – Vol. 15. – P. 433–450.
20. Diel R., Goletti D., Ferrara G. et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and
meta-analysis. // Eur. Respir. J. – 2011. – Vol. 37. – N. 1. – P. 88-99.
21. Ernst J. The immunological life cycle of tuberculosis // Nat. Rev. Immunol. – 2012. – Vol. 12. – N. 8. – P. 581-591.
22. Esmail H., Barry E., Wilkinson R. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. //
Drug. Discov. Today. – 2012. – Vol. 17. – N. 9-10. – P. 514-521.
23. Garton N., Waddell S., Sherratt A. et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum // PLoS Med. –
2008. – Vol. 5. – N. 4. – e75.
24. Govender L., Abel B., Hughes E. et al. Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and
Rv2659 in latent infection compared with tuberculosis disease. // Vaccine. – 2010. – Vol. 29. – N. 1. – P. 51-57.
25. Harari A., Rozot V., Bellutti Enders F. et al. Dominant TNF-alpha(+) Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent
infection and active disease. // Nat. Med. – 2011. – Vol. 17. – N. 3. – P. 372-376.
26. Harboe M., Oettinger T., Wiker H. et al. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and
for its absence in Mycobacterium bovis BCG. // Infect. Immun. – 1996. – Vol. 64. – N. 1. – P. 16-22.
27. Hinks T., Dosanjh D., Innes J. et al. Frequencies of region of difference 1 antigen-specific but not purified protein derivative-specific gamma
interferon-secreting T cells correlate with the presence of tuberculosis disease but do not distinguish recent from remote latent infections. // Infect. Immun. –
2009. – Vol. 77. – N. 12. – P. 5486-5495.
28. Horsburgh C. Priorities for the treatment of latent tuberculosis infection in the United States. // N. Engl. J. Med. – 2004. – Vol. 350. – N. 20. – P. 2060-2067.
29. Johnson P., Stuart R., Grayson M. et.al. Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical
students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis // Clin. Diagn. Lab. Immunol. – 1999. – Vol. 6. – N. 6. –
P. 934-937.
30. Kunnath-Velayudhan S., Gennaro M. Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery. // Clin. Microbiol. Rev. – 2011. – Vol. 24. –
N. 4. – P. 792-805.
31. Lalvani A., Pareek M. A 100 year update on diagnosis of tuberculosis infection. // Br. Med. Bull. – 2010. – Vol. 93. – P. 69-84.
32. Lawn S., Wood R., Wilkinson R. Changing concepts of «latent tuberculosis infection» in patients living with HIV infection. // Clin. Dev. Immunol. – 2011:
pii: 980594.
33. Lin P., Rodgers M., Smith L. et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. // Infect. and Immun. –
2009. – Vol. 77. – N. 10. – P. 4631-4642.
34. Mack U., Migliori G., Sester M. et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. //
Eur. Respir. J. – 2009. – Vol. 33. – P. 956-973.
35. Mazurek G., Jereb J., Vernon A. et al. Updated guidelines for using interferon gamma release Assays to detect Mycobacterium tuberculosis infection. //
MMWR Recomm. Rep. – 2010. – Vol. 59. – P. 1-25.
36. Menzies D., Pai M., Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations
for research. // Ann. Intern. Med. – 2007. – Vol. 146. – P. 340-354.
37. Millington K., Innes J., Hackforth S. et al. Dinamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and
antigen load. // J. Immunol. – 2007. – Vol. 178. – N. 8. – P. 5217-5226.
38. Millington K., Fortune S., Low J. et al. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific
for Mycobacterium tuberculosis infection. // Proc. Natl. Acad. Sci. USA. – 2011. – Vol. 108. – N. 14. – P. 5730-5735.
39. Mori T., Sakatani M., Yamagishi F. et al. Specific detection of tuberculosis infection: An interferon-gamma-based assay using new antigens. // Am. J. Respir.
Crit. Care Med. – 2004. – Vol. 170. – P. 59-64.
40. Pai M., Kalantri S., Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. // Expert. Rev. Mol. Diagn. –
2006. – Vol. 6. – P. 413-422.
41. Park H., Guinn K., Harrell M. et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. //
Mol. Microbiol. – 2003. – Vol. 48. – P. 833-843.
42. Peyron P., Vaubourgeix J., Poquet Y. et.al. Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. tuberculosis
persistence // PLoS. Pathog. – 2008. – Vol. 4. – N. 11. – e1000204.
43. Rangaka M., Diwakar L., Seldon R. et al. Clinical, Immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected
Africans. // Clin. Infect. Dis. – 2007. – Vol. 44. – P. 1639-1646.
44. Rangaka M., Wilkinson K., Glynn J. et al. Predictive value of interferon-γ release assay for incident active tuberculosis: a systematic review and meta-analysis //
Lancet Infect. Dis. – 2012. – Vol. 12. – N. 1. – P. 45-55.
45. Rieder H. Socialization patterns are key to the transmission dynamics of tuberculosis // Int. J. Tuberc. Lung. Dis. – 1999. – Vol. 3. – N. 3. – P. 177-178.
46. Rueda C., Martin N., Garcia L., Rojas M. Characterization of CD4 and CD8 T cells producing INF-gamma in human latent and active tuberculosis //
Tuberculosis (Edinb). – 2010. – Vol. 90. – N. 6. – P. 346-353.
47. Russell D., Cardona P., Kim M. et al. Foamy macrophages and the progression of the human tuberculosis granuloma // Nat. Immunol. – 2009. – Vol. 10. –
N. 9. – P. 943-948.
48. Rustad T., Harrell M., Liao R. Sherman D. The enduring hypoxic response of Mycobacterium tuberculosis. In: The immunological life cycle of tuberculosis //
Nat. Rev. Immunol. – 2012. – Vol. 12. – N. 8. – P. 581-591.
49. Sargentini V., Mariotti S., Carrara S. et al Cytometric detection of antigen-specific INF-gamma/IL-2 secreting cells in the diagnosis of tuberculosis. //
BMC Infect. Dis. – 2009. – Vol. 9. – P. 99.
50. Schluger N., Burzynski J. Recent advances in testing for latent TB. // Chest. – 2010. – Vol. 138. – N. 6. – P. 1456-1463.
51. Schnappinger D., Ehrt S., Voskuil M. et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal
environment // J. Exp. Med. – 2003. – Vol. 198. – N. 5. – P. 693-704.
52. Schuck S., Mueller H., Kunitz F. et.al. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection // PLoS One. – 2009. – Vol. 4. –
N. 5. – e5590.
53. Serra-Vidal M., Latorre I., Franken K. et al. Immunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosis. // Front. Microbiol. –
2014. – Vol. 5. – P. 517.
54. Sester M., Sotqiu G., Lanqe C. et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. //
Eur. Respir. J. – 2011. – Vol. 37. – N. 1. – P. 100-111.
55. Vekemans J., Lienhardt C., Sillah J. et al. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community
controls in The Gambia. // Infect. Immun. – 2001. – Vol. 69. – N. 10. – P. 6554-6557.
56. Wallis R., Pai M., Menzies D. et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. // Lancet. – 2010. – Vol. 375. –
P. 1920-1937.
57. Wergeland I., Assmus J., Dyrhol-Riise A. et al. T regulatory cells and immune activation in Mycobacterium tuberculosis infection and effect of preventive
therapy. // Scand. J. Immunol. – 2010. – Vol. 73. – N. 3. – P. 234-242.
58. Wyndham-Thomas C., Corbière V., Dirix V. et al. Key role of effector memory CD4+ T lymphocytes in a short-incubation heparin-binding hemagglutinin
gamma interferon release assay for the detection of latent tuberculosis // Clin. Vaccine Immunol. – 2014. – Vol. 21. – N. 3. – P. 321-328.
59. Zhang T., Li S., Williams K. et al. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection //
Am. J. Respir. Crit. Care Med. – 2011. – Vol. 184. N. 6. – P. 732-737
